Untitled

JSB Market Research Pvt. Ltd.
Email ID- contact@jsbmarketresearch.com

Tel No- 91 2241236650 / +91 - 998 729 5242
Published by- http:/www.jsbmarketresearch.com/

Biomarkers Market (Diagnostic Applications in Risk Assessment,
Molecular Diagnostics, Disease Diagnosis, Drug Discovery &
Development, Drug Formulation, Forensic Applications and Others)
- Global Industry Analysis, Emerging Technologies, Competitive
Intelligence, Growth Trends, Size, Share, Opportunities and
Forecast, 2013 - 2020
Released On 15
th
July 2014

Biomarker technology is evidencing increased application from key segments such as
disease diagnosis, drug development and formulation, diagnosis for exposure of
certain harmful chemical and prognostic treatments. Biomarkers are novel diagnostic
solutions and advancement in it its development and understanding of human genome
promotes its application in diagnosis of disease on molecular basis. Pharmaceutical
companies which are interested in introducing novel diagnostic solution are increasing
partnership and collaboration with private laboratories, educational institute and these
companies are also increasing their investments in research and development.

The global market for diagnostic biomarker expected to reach about $30.6 billion in
2020 growing at CAGR of 16% from 2013 to 2020. Disease diagnostic application
remains the key area of application that is expected to reach 6.1 $billion in 2020.
However application of diagnostic biomarkers in forensics and molecular diagnostics

Tel No- 91 2241236650 / +91 - 998 729 5242

is catching up quite significantly. Molecular diagnostics is expected to grow at a
CAGR of 17.6% from 2013 to 2020.
Scope

Global diagnostic Biomarker report segments the market in three categories; market
by technologies, market by services, and market by diseases. These markets are
expected to show elevated growth in future as biomarkers are providing diagnostic
service for complex disease. As it is non-invasive procedure it motivates the use of
biomarkers than conventional diagnostic applications. This report focuses on key
factors impacting the diagnostic biomarker market used in risk assessment,
molecular diagnostics, disease diagnosis, drug discovery and development, drug
formulation, forensic applications and others. Diagnostic biomarker and its
applications in emerging segments of omics, imaging technologies, personalized
medicine, and bioinformatics are all discussed in detail.

Key deliverables

Biomarkers of disease are majorly covered by oncology, cardiovascular and
Neurology disease. Oncology biomarkers are covering more market share as
compared to other disease biomarkers. Other biomarker are facing some ethical and
technical problem such complex sample preparation process.

Biomarkers in service has open a new market for sample preparation for disease
diagnosis which enables clinicians to save time required for preparing sample to
conduct diagnostic test. Biomarkers are also resolving drug validation problem by
analyzing viability of drug discovered by pharmaceutical research.

The geographic analysis is based on North America., Europe, Asia-Pacific and Rest of
the World.

The key players in this market that are also profiled in the report include Roche
Diagnostic Limited (Switzerland), Siemens Healthcare (Germany), Abbott
Laboratories Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies
Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), Aushon BioSystem Inc. (M.A.),
Epistem Ltd.(U.K.), G.E. Healthcare Inc.(U.K).

Tel No- 91 2241236650 / +91 - 998 729 5242

Key benefits of report

Assessment and ranking the factors that favour the market growth and those factors
which act as a hindrance for the growth of the market
The market sizing and estimation period is from 2013 to 2020. Two historic years
include 2011 and 2012
The report identifies and analyses top investment pockets and top winning strategies
for diagnostic biomarker market
The report analyses the various strategies adopted by some of the key companies in
the market
The report tracks and analyses key innovations and patents for biomarkers in the last
five years
Table of Contents
1. Introduction
1.1 Scope and Coverage
1.2 Report Description
2 Summary
2.1 Biomarker Diagnosis Vs. Conventional Diagnosis
2.2 Why Diagnostic Biomarkers are Used in Diagnosis and Drug Development?
3 Market Overview
3.1 Key Application of Diagnostic Biomarkers in Top Technologies
3.1.1 Omics Technology

Tel No- 91 2241236650 / +91 - 998 729 5242

3.1.1.1 Applications of Omics Technology
3.1.1.1.1 Lung Disease Identification
3.1.1.1.2 Quantifying Abnormalities
3.1.1.1.3 Genetic Trait Diagnosis
3.1.1.1.4 Analyzing Drug Efficiency
3.1.1.1.5 Functional Food Development
3.1.1.1.6 Pharmacogenomics
3.1.1.1.7 Drivers
3.1.1.1.8 Restraints
3.1.1.1.8.1 Lengthy Process
3.1.1.1.8.2 Ethical Problems
3.1.1.1.8.3 Sample Collection
3.1.1.1.8.4 Gene Expression
3.1.1.1.8.5 Inefficiency in Pre-Disease Identification
3.1.2 Imaging Technology
3.1.2.1 Application of Diagnostic Imaging Technology
3.1.2.2 Drivers
3.1.2.2.1 Faster Test Result

Tel No- 91 2241236650 / +91 - 998 729 5242

3.1.2.2.2 Improved Nursing Services
3.1.2.2.3 Noninvasive Technique
3.1.2.3 Restraints
3.1.2.3.1 Radiation Effect
3.1.2.3.2 Complex Process
3.1.2.3.3 Genetic Variation
3.1.2.4 Trends
3.1.3 Bioinformatics
3.1.3.1 Applications of Bioinformatics
3.1.3.2 Drivers
3.1.3.2.1 Open Source of Information
3.1.3.2.2 Relevant Information
3.1.3.2.3 Forecasting of Information
3.1.3.3 Restraints
3.1.3.3.1 Difficulty in Practical Application
3.1.3.3.2 Over-Fitting
3.1.3.3.3 Complex Operation Process
3.1.3.3.4 Security Issue

Tel No- 91 2241236650 / +91 - 998 729 5242

3.1.3.3.5 Costly Management
3.1.3.3.6 Virtual Storage
3.1.4 Personalized Medicines
3.1.4.1 Drivers
3.1.4.1.1 Unique Solution
3.1.4.1.2 Minimal Invasive
3.1.4.1.3 Reduction in Failure
3.1.4.1.4 Effective Prescription
3.1.4.2 Restraints
3.1.4.2.1 Need Specialized Setup for Treatment
3.1.4.2.2 Liability Issue
3.1.4.2.3 Ethical Question
3.1.5 Others (Nutritional Technology)
3.2 Importance of Non-Invasive Diagnostics
3.3 Key Advantages of Dm
3.4 Regulatory Scenario
3.5 Reimbursement Issues
3.6 Key Patents and Analysis

Tel No- 91 2241236650 / +91 - 998 729 5242

3.7 Top Ten Factors Impacting DBM Market
3.7.1 Non-Invasive Technique
3.7.2 Drug Discovery and Development
3.7.3 Cost Effective Tool for Diagnosis
3.7.4 Multi-Marker Application
3.7.5 Accuracy and Reliability
3.7.6 Ethical Issues
3.7.7 Gene Level Diagnosis
3.7.8 Complex Processes
3.7.9 Government Regulations
3.7.10 Reimbursement Issues
3.8 Top Investment Pockets
3.9 Market Intelligence
3.9.1 Top Three Winning Strategies
3.9.1.1 Product Launch
3.9.1.2 Collaboration and Agreement
3.9.1.3 Merger and Acquisition
3.10 Market Dynamics

Tel No- 91 2241236650 / +91 - 998 729 5242

3.10.1 Drivers
3.10.1.1 Cost Effective
3.10.1.2 Non-Invasive
3.10.1.3 Accuracy in Result
3.10.1.4 Assistant in Clinical Trials
3.10.1.5 Multi-Marker Application
3.10.1.6 Gene Level Diagnosis
3.10.2 Restrains
3.10.2.1 Government Regulation
3.10.2.2 Ethical Problems
3.10.2.3 Conformation in Result
3.10.2.4 Complex Process
3.10.3 Opportunity
3.10.3.1 Local Market
3.10.3.2 Personalized Medicine
3.10.3.3 Tissue Specific Treatment
4 Global Diagnostic Biomarker Market by Types
4.1 Biomarker of Exposure

Tel No- 91 2241236650 / +91 - 998 729 5242

4.2 Biomarkers of Disease
5 Global Diagnostic Biomarker Market by Applications
5.1 Risk Assessment
5.1.1 Applications
5.1.1.1 Oncology Treatment
5.1.1.2 Cardiovascular Treatment
5.1.2 Drivers
5.1.2.1 Forecasting of Abnormal Conditions
5.1.3 Restraints
5.1.3.1 Government Regulations
5.1.3.2 Ethical Issues
5.2 Development of Molecular Diagnostic
5.2.1 Application
5.2.1.1 Prenatal Diagnostics
5.2.1.2 Human Clinical Molecular Diagnostic Testing
5.2.1.3 Veterinary Molecular Diagnostic Testing
5.2.1.4 Identity Testing

Tel No- 91 2241236650 / +91 - 998 729 5242

5.2.1.5 Histocompatibility Testing
5.2.2 Drivers
5.2.2.1 Uniformity in Test Result
5.2.2.3 Fast Result
5.2.2.4 More Profitable
5.2.2.5 Automation
5.2.3 Restraints
5.2.3.1 Not Applicable for Twins Genomes
5.2.3.2 Government Regulations
5.2.3.3 Ethical Issues
5.3 Disease Diagnosis
5.3.1 Oncology
5.3.1.1 Drivers
5.3.1.2 Restraints
5.3.1.2.2 Conformation in Result
5.3.1.2.3 Used for Early Diagnosis Only

Tel No- 91 2241236650 / +91 - 998 729 5242

5.3.2 Cardiology
5.3.2.1 Application
5.3.2.2 Drivers
5.3.2.2.1 Cost Effective
5.3.2.2.2 Tissue Specific
5.3.2.2.3 Accurate Result
5.3.2.3 Restraints
5.3.2.3.1 Loss of Specificity
5.3.2.3.2 Low Specificity
5.3.2.3.3 Low Sensitivity
5.3.3 Neurology
5.3.3.1 Application
5.3.3.2 Drivers
5.3.3.2.1 Relevant Information
5.3.3.2.2 Efficient Diagnosis
5.3.3.2.3 Assistant in Clinical Trials
5.3.3.3 Restraints

Tel No- 91 2241236650 / +91 - 998 729 5242

5.3.3.3.2 Chromosomal Variation
5.3.3.3.3 Hurdles in Tracking
5.3.3.4 Alzheimers
5.3.3.5 Multiple Sclerosis
5.3.3.6 Parkinsons Disease
5.3.3.7 Others (Renal Diseases, Urinal Disease)
5.4 Drug Discovery and Development
5.4.1 Application
5.4.2 Drivers
5.4.2.1 Increased Efficiency
5.4.2.2 High Quality Support
5.4.2.4 Collaboration for Novel Development
5.4.3 Restraints
5.4.3.1 Drug Metabolism
5.4.3.2 Stability of Biomarkers
5.4.3.3 Complex Process
5.5 Drug Formulation

Tel No- 91 2241236650 / +91 - 998 729 5242

5.5.1 Application
5.5.2 Drivers
5.5.3 Restraint
5.6 Forensic Application
5.7 Others (Dna Fingerprinting and Others)
5.7.1 Blood Alcohol Concentration Biomarker
5.7.2 Dna Fingerprinting
6 Global Diagnostic Biomarker Market by Services
6.1 Sample Preparation
6.1.1 Application
6.1.1.1 Biological Mass Spectrometry
6.1.2 Drivers
6.1.2.2 Sample Rigidity
6.1.2.3 Efficient Forensic Studies
6.1.3 Restraints
6.1.3.1 Complex Structure
6.1.3.2 Lack of Effectiveness

Tel No- 91 2241236650 / +91 - 998 729 5242

6.1.3.3 Extensive Fractionation
6.1.3.4 Loss of Biological Compounds
6.2 Assay Development
6.2.1 Application
6.2.1.1 Clinical Trials
6.2.1.2 Drug Development and Validation
6.2.1.3 Others
6.2.2 Drivers
6.2.2.1 Accuracy
6.2.2.3 Timely Result
6.2.3 Restraints
6.2.3.1 Complexity in Technique
6.2.3.2 Tissue Specific
6.3 Biomarker Validation and Testing
6.3.1 Drivers
6.3.1.1 Reduce Failure Rate
6.3.2 Restraints

Tel No- 91 2241236650 / +91 - 998 729 5242

6.3.2.1 Clinical Errors
6.3.2.2 Time Consuming
6.4 Other Services
7 Global Diagnostic Biomarker Market by Geography
7.1 North America
7.2 Europe
7.3 Asia-Pacific
7.4 Row (Rest of World)
8 Competitive Landscape
8.1 Product Launch
8.1.1 Recent Development
8.2 Collaboration and Partnership
8.3 Clearance and Approval
8.4 Mergers and Acquisition
9 Company Profile

Tel No- 91 2241236650 / +91 - 998 729 5242

9.1 Abbott Laboratories, Inc.
9.1.1 Company Overview
9.1.2 Company Snapshot
9.1.3 Business Performance
9.1.4 Strategic Moves and Developments
9.1.4.1 Principal Strategies
9.1.4.2 Secondary Strategies
9.1.5 Swot Analysis & Strategic Conclusions
9.2 Agilent Technologies Inc.
9.2.1 Company Overview
9.2.4.1 Primary Strategies
9.3 Aushon Biosystem
9.3.1 Company Profile

Tel No- 91 2241236650 / +91 - 998 729 5242

9.4 Bio-Rad Laboratories
9.5 Eisai Co. Ltd.

Tel No- 91 2241236650 / +91 - 998 729 5242

9.6 Epistem Ltd.
9.7 Ge Healthcare
9.7.4.1 Principle Strategies

Tel No- 91 2241236650 / +91 - 998 729 5242

9.8 Roche Diagnostics Limited
9.8.4.1 Principal Strategies
9.9 Siemens AG
9.10 Thermo Fisher Scientific Inc.

Tel No- 91 2241236650 / +91 - 998 729 5242

List of Tables
Table 1 Global Diagnostic Biomarker Market by Revenue 2011-2020 ($Million)
Table 2 Global Diagnostic Biomarker Market by Application 2011-2020 ($Million)
Table 3 Global Diagnostic Biomarker Market for Technology 2011-2020 ($Million)
Table 4 Diagnostic Biomarker Application Market 2011-2020 ($Million)
Table 5 Diagnostic Biomarker Application Market 2011-2020 ($Million)
Table 6 Global Diagnostic Biomarker Market of Imaging Technology 2011-2020
($Million)
Table 7 Global Diagnostic Biomarker Market of Bioinformatics 2011-2020
($Million)
Table 8 Global Diagnostic Biomarker Market of Personalized Medicine 2011-2020
($Million)

Tel No- 91 2241236650 / +91 - 998 729 5242

Table 9 Global Diagnostic Biomarker Market of Other Diseases 2011-2020
($Million)
Table 10 Biomarkers Market by Types in 2011-2020 ($Million)
Table 11 Global Market for Biomarkers of Exposure in 2011-2020 ($Million)
Table 12 Global Market for Biomarkers of Exposure in 2011-2020 ($Million)
Table 13 Diagnostic Biomarker Application Market in 2011-2020 ($Million)
Table 14 Global Diagnostic Biomarker Market Application Market in 2011-2020
($Million)
Table 15 Global Diagnostic Biomarker Market of Risk Assessment in 2011-2020
($Million)
Table 16 Global Diagnostic Biomarker Market for Development of Molecular
Diagnostic in 2011-2020 ($Million)
Table 17 Diagnostic Biomarker Market of Disease Diagnosis in 2011-2020
($Million)
Table 18 Global Diagnostic Biomarker Market for Development of Molecular
Diagnostic in 2011-2020 ($Million)
Table 19 Global Diagnostic Biomarker Market of Cardiology Diagnosis in 2011-
2020 ($Million)
Table 20 Global Diagnostic Biomarker Market of Cardiology Diagnosis in 2011-
2020 ($Million)
Table 21 Global Diagnostic Biomarker Market of Neurology Diagnosis in 2011-
2020 ($Million)

Tel No- 91 2241236650 / +91 - 998 729 5242

Table 22 Diagnostic Biomarker Market for Neurology Disease Diagnosis in 2011-
2020 ($Million)
Table 23 Global Diagnostic Biomarker Market of Other Disease Diagnosis in 2011-
2020 ($Million)
Table 24 Global Diagnostic Biomarker Market of Other Disease Diagnosis in 2011-
2020 ($Million)
Table 25 Global Diagnostic Biomarker Market of Drug Formulation in 2011-2020
($Million)
Table 26 Global Diagnostic Biomarker Market of Forensic Application in 2011-
2020 ($Million)
Table 27 Global Diagnostic Biomarker Market of Other Diseases in 2011-202
($Million)
Table 28 Diagnostic Biomarker Market of Services in 2011-202($Million)
Table 29 Global Diagnostic Biomarker Market of Services in 2011-2020 ($Million)
Table 30 Global Diagnostic Biomarker Market of Sample Preparation in 2011-2020
($Million)
Table 31 Global Diagnostic Biomarker Market of Assay Development in 2011-2020
($Million)
Table 32 Global Diagnostic Biomarker Market of Biomarker Validation in 2011-
2020 ($Million)
Table 33 Global Diagnostic Biomarker Market of Other Services in 2011-2020
($Million)
Table 34 Global Diagnostic Biomarker Market in 2011-2020 ($Million)

Tel No- 91 2241236650 / +91 - 998 729 5242

Table 35 Types of Developments From 2013-2010
Table 36 Recent Development in Product Launch

Table 37 Product Launches From 2013-2010
Table 38 Collaboration and Partnership
Table 39 Partnership and Collaboration From 2013-2010
Table 40 Recent Development in Clearance and Approval
Table 41 Diagnostic Biomarker Approval and Clearance From 2013-2010
Table 42 Recent Development in Mergers and Acquisition
Table 43 Merger and Acquisition From 2013-2010
Table 44 Abbott Laboratories Business Snapshot
Table 45 Agilent Technologies Inc. Business Snapshot
Table 46 Aushon Biosystem Business Snapshot
Table 47 Bio-Rad Laboratories Business Snapshot
Table 48 Eisai Co. Ltd Business Snapshot
Table 49 Epistem Company Business Snapshot
Table 50 GE Healthcare Business Snapshot
Table 51 Roche Diagnostics Limited Business Snapshot

Tel No- 91 2241236650 / +91 - 998 729 5242

Table 52 Siemens Inc. Business Snapshot
Table 53 Thermo Fisher Scientific Inc. Business Snapshot
List of Figures
Figure 1 Patents Application Filled by General Electrical for Imaging Technology in
India (2012)
Figure 2 Spider-Chart for Changes in Key Advantages From 2013-2020
Figure 3 Expected Growth of Biomarkers Application for Cancer Testing
Figure 4 Patent Analysis by Geography 2013
Figure 5 Top 10 Key Strategies Spider Chart 2012-2020
Figure 6 Expected Growth in CAGR From 2011-2020 for Diagnostic Biomarker
Technology
Figure 7 Expected Growth in CAGR From 2011-2020 for Diagnostic Biomarkers in
Application
Figure 8 Expected Growth in CAGR From 2011-2020 for Diagnostic Biomarkers in
Services
Figure 9 Top 3 Wining Strategies From 2012-2020
Figure 10 Top 10 Countries in Cancer Population (Per 100,000 People) 2011
Figure 11 Cancer Statistics for Estimated New Cases and Deaths in U.S. for 2012
Figure 12 Leading Causes of Mortality in U.S. 2012
Figure 13 Cost on Alzheimer`S Disease to U.S. in 2013 (in Billion)

Tel No- 91 2241236650 / +91 - 998 729 5242

Figure 14 Estimated Deaths Vs. Estimated Cases in Different Types of Cancer in
North America 2013
Figure 15 Developmental Strategies Adopted From 2013-2010
Figure 16 Diagnostic Biomarker Product Launch by Companies From 2013-2010
Figure 17 Partnership and Collaboration of Companies From 2013-2010
Figure 18 Clearance and Approval of Top 5 Companies From 2013-2010
Figure 19 Mergers and Acquisition From 2013-2010
Figure 20 Abbott Laboratories, Inc. Financial Revenues by Business Units (2012)
Figure 21 Abbott Laboratories, Inc. Financial Revenues by Geography (2012)
Figure 22 SWOT Analysis of Abbott Laboratories
Figure 23 Agilent Technologies Inc. Financial Revenues by Business Units (2012)
Figure 24 Agilent Technologies Inc. Financial Revenues by Geography (2012)
Figure 25 SWOT Analysis of Agilent Technologies
Figure 26 SWOT Analysis of Aushon Biosystem
Figure 27 Bio-Rad Laboratories Financial Revenues by Business Units (2012)
Figure 28 Bio-Rad Laboratories Financial Revenues by Geography (2012)
Figure 29 SWOT Analysis of Bio-Rad Laboratories
Figure 30 Eisai Co. Ltd Financial Revenues by Business Units (2012)
Figure 31 Eisai Co. Ltd Financial Revenues by Geography (2012)

Tel No- 91 2241236650 / +91 - 998 729 5242

Figure 32 SWOT Analysis of Eisai Co. Ltd
Figure 33 Epistem Financial Revenues by Business Units (2012)
Figure 34 Epistem Financial Revenues by Geography (2012)
Figure 35 SWOT Analysis of Epistem
Figure 36 GE Healthcare Financial Revenues by Business Units (2012)
Figure 37 GE Healthcare Financial Revenues by Geography (2012)
Figure 38 SWOT Analysis GE Healthcare
Figure 39 Roche Diagnostics Limited Financial Revenues by Business Units (2012)
Figure 40 Roche Diagnostics Limited Financial Revenues (Diagnostic Division) by
Geography (2012)
Figure 41 SWOT Analysis of Roche Diagnostics Limited
Figure 42 Siemens Inc. Financial Revenues by Business Units (2012)
Figure 43 Siemens Inc. Financial Revenues by Geography (2012)
Figure 44 SWOT Analysis of Siemens
Figure 45 Thermo Fisher Scientific Inc. Financial Revenues by Business Units
(2012)
Figure 46 Thermo Fisher Scientific Inc. Financial Revenues by Geographic Areas
(2012)
Figure 47 SWOT Analysis of Thermo Fisher Scientific Inc

Tel No- 91 2241236650 / +91 - 998 729 5242

Related reports:
Global Clean Coal Technologies Market 2014-2018
Global Transdermal Drug Delivery Market 2014-2018
Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018
Healthcare and Medical Market Research

About JSB Market Research:-
JSB market research is a leading player in the market of research report
distribution. It is one-stop-shop for all information related to market research for
any sector of the industry. Along with providing in-depth analysis though reports,
JSB market research also provides regular updates of the market though
newsletters. Our reports are a well-researched work of market researchers with an
extensive knowledge and a good level of market experience.
To know more on JSB Market Research : Biomarkers Market (Diagnostic
Applications in Risk Assessment, Molecular Diagnostics, Disease Diagnosis,
Drug Discovery & Development, Drug Formulation, Forensic Applications
and Others) - Global Industry Analysis, Emerging Technologies, Competitive
Intelligence, Growth Trends, Size, Share, Opportunities and Forecast, 2013 -
2020)
http://www.jsbmarketresearch.com/healthcare-medical/r-Biomarkers-
Market-Global-Industry-Analysis-Emerging-Technologies-Competitive-
Intelligence-65371

Untitled

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Untitled

Uploaded by

Copyright:

Available Formats

JSB Market Research Pvt. Ltd.

Email ID- contact@jsbmarketresearch.com

You might also like